← Back to Search

Tyrosine Kinase Inhibitor

Pembrolizumab for Thyroid Cancer

Phase 2
Waitlist Available
Led By Bryan R Haugen
Research Sponsored by Academic and Community Cancer Research United
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial is testing a combination of two drugs to treat patients with advanced thyroid cancer.

Eligible Conditions
  • Unresectable Differentiated Thyroid Cancer
  • Papillary Thyroid Carcinoma
  • Thyroid Cancer
  • Papillary Thyroid Cancer
  • Thyroid Gland Carcinoma
  • Differentiated Thyroid Gland Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Papillary Carcinoma
  • Hurthle Cell Carcinoma
  • Thyroid Carcinoma
  • Papillary Carcinoma of the Thyroid Gland

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Complete Response Rate (Cohort 1)
Confirmed Response Rate (Cohort 2)
Secondary outcome measures
Number of Patients Experiencing Grade 3+ Adverse Events
Overall Survival (OS)
Progression Free Survival (PFS)
Other outcome measures
Biomarker Levels Analysis Following Pembrolizumab and Lenvatinib Combination Therapy

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Kidney Injury and/or Infection
7%
Pneumonia
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Activated partial thromboplastin time prolonged
5%
Intractable pain, back pain, hip pain
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Skin rash
2%
Thrombocytopenia
2%
Respiratory failure
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (lenvatinib, pembrolizumab)Experimental Treatment4 Interventions
Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenvatinib
2005
Completed Phase 4
~2690
Pembrolizumab
2017
Completed Phase 2
~1950
Lenvatinib Mesylate
2016
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Academic and Community Cancer Research UnitedLead Sponsor
53 Previous Clinical Trials
5,079 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,589 Total Patients Enrolled
Bryan R HaugenPrincipal InvestigatorAcademic and Community Cancer Research United

Media Library

Thyroid Cancer Research Study Groups: Treatment (lenvatinib, pembrolizumab)
Thyroid Cancer Clinical Trial 2023: Lenvatinib Highlights & Side Effects. Trial Name: NCT02973997 — Phase 2
Lenvatinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02973997 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare facilities have been approved to conduct this investigation?

"Across the country, there are 7 medical centres taking part in this clinical trial. These include Memorial Sloan Kettering Cancer Center (New york), Ohio State University Comprehensive Cancer Center (Columbus) and Massachusetts General Hospital Cancer Centre (Boston). Additionally, 4 other sites are participating too."

Answered by AI

To what diseases is the therapeutic Pembrolizumab typically prescribed?

"Pembrolizumab is an effective treatment for malignant neoplasms, inoperable melanoma, and microsatellite instability high cancers."

Answered by AI

Is this experiment in need of new participants?

"Unfortunately, this particular medical trial is not presently seeking new participants. The protocol was originally uploaded on February 7th 2018 and last amended on January 5th 2022. If you are searching for other trials, there are currently 3443 opportunities to join a study related to thyroid (usp), as well as 1032 possibilities involving Pembrolizumab therapy."

Answered by AI

Could you provide any details on prior research conducted in regards to Pembrolizumab?

"At present, 1032 Pembrolizumab trials are taking place with 134 of them being in the third phase. While Sacramento, California has a high concentration of studies for this drug, there exist 37061 clinics worldwide conducting research on it."

Answered by AI

How many individuals have been accepted into this clinical trial thus far?

"Unfortunately, enrollment for this trial closed on January 5th 2022. The study was initially posted four years prior in February 2018. For those looking to participate in similar trials now, there are 3443 studies involving thyroid (usp) and 1032 Pembrolizumab-based studies actively recruiting patients at present."

Answered by AI

Is Pembrolizumab a risk-free treatment option for patients?

"There is limited clinical evidence for Pembrolizumab's safety, resulting in it receiving a rating of 2."

Answered by AI
~8 spots leftby Mar 2025